STOCK TITAN

ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

ALX Oncology Holdings (Nasdaq: ALXO) announced participation in the Jefferies 2022 Healthcare Conference on June 8 at 10:00 am ET. CEO Jaume Pons, Ph.D. will engage in a fireside chat during this event, highlighting the company's clinical-stage immuno-oncology advancements.

A live webcast is available on their website and will be archived for 90 days post-event. ALX Oncology is known for developing therapies targeting the CD47 checkpoint pathway, with its lead candidate evorpacept showing promise in treating various cancers.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2022 Healthcare Conference on Wednesday, June 8 at 10:00 am ET in New York.

A live webcast of the fireside chat is available here and can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcasts will be archived for up to 90 days following the fireside chat dates.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.


FAQ

What is the date and time of ALXO's participation in the Jefferies 2022 Healthcare Conference?

ALXO will participate in the Jefferies 2022 Healthcare Conference on June 8 at 10:00 am ET.

Who will represent ALXO at the Jefferies 2022 Healthcare Conference?

Jaume Pons, Ph.D., the Founder, President, and CEO, will represent ALXO at the conference.

How can I access the webcast of ALXO's fireside chat?

The webcast can be accessed through the Investors section of ALX Oncology's website or directly via the link provided in the PR.

What is evorpacept and its significance for ALXO?

Evorpacept is ALX Oncology's lead product candidate, targeting the CD47 checkpoint pathway, showing promising clinical responses in various cancer types.

How long will the webcast of the fireside chat be available after the event?

The webcast will be available for replay for up to 90 days following the fireside chat.

ALX Oncology Holdings Inc.

NASDAQ:ALXO

ALXO Rankings

ALXO Latest News

ALXO Stock Data

81.22M
41.97M
1.97%
88.23%
13.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO